Curis, Inc. · NASDAQ:CRIS

Curis — EHA 2022 Hybrid Congress

15 slides from Curis's conference presentation, Jun 11, 2022

  1. Slide 1: EHA 2022 Hybrid, June 9-17, Vienna

  2. Slide 2: TakeAim Leukemia: Phase 1/2a Study of Emavusertib in R/R AML or MDS

    TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS Guillermo Garcia-Manero, MD1, Eric S. Winer, MD2, Daniel J. DeAngelo, MD, PhD2, Stefano Tarantolo, MD3, David A. Sallman

  3. Slide 3: Disclosures

    Disclosures Research support from: Curis, Astex, Abbvie, BMS, Jazz, Novartis, Aprea, ALX, Gilead, Seattle Genetics

  4. Slide 4: Emavusertib, An Oral IRAK4 Inhibitor

    Emavusertib, An Oral IRAK4 Inhibitor IRAK4/Emavusertib Co-crystal Structure Emavusertib: • Selective, small molecule inhibitor of IRAK4 • ATP-competitive, type 1 inhibitor, reversible • Excellent drug-like properties: o Orally bioavailable (>100% dog/mouse) o Moderate plasma binding (77% human) o St

  5. Slide 5: Emavusertib: Introduction

    Emavusertib: Introduction • Emavusertib (CA-4948), a novel oral IRAK4 inhibitor has Normal Heme Cell1 Malignant Heme Cell1 potential anti-leukemia activity Spliceosome Spliceosome Spliceosome • Specific genetic mutations (SF3B1, U2AF1) in the Mutation spliceosome drive overexpression of IRAK4 long i

  6. Slide 6: Preclinical Activity in AML and MDS

    Emavusertib: Preclinical Activity in AML and MDS Monotherapy Combination Therapy p<0.05 100 Vehicle Relative Cell Growth % p<0.05 50 p<0.05 Emavusertib reduces leukemic blasts in monotherapy 0 Relative Cell Death % Control Ven Ven Aza Aza Aza/Ven + + Emavusertib emavusertib emavusertib 50 AML cell l

  7. Slide 7: Study Design

    Emavusertib: Study Design TakeAim Leukemia (NCT #04278768): Open-label, single arm, Phase 1/2 dose escalation and expansion 3+3 study design in R/R AML or high-risk MDS (HR-MDS) Study Objectives Dose Escalation: Dose Expansion: 1ᵒ: Determine maximum tolerated dose 200/300/400/500 mg BID 300 mg BID D

  8. Slide 8: Baseline Characteristics

    Emavusertib: Baseline Characteristics AML/MDS Subsets All patients 1 1 AML Spliceosome MDS Spliceosome AML FLT3 (n=49) (n=6) (n=7) (n=3) Female n (%) : Male n (%) 16 (33) : 33 (67) 0 (0) : 6 (100) 5 (71) : 2 (29) 0 (0) : 3 (100) Age (yrs): median (range) 74 (32, 87) 76 (60, 84) 74 (61, 80) 80 (78, 8

  9. Slide 9: Toxicities Profile

    Emavusertib: Toxicities Profile • During the initial dose escalation phase, no DLT was observed in 200-400 mg BID dose levels. Additional patients were enrolled at 300 mg and 400 mg BID to further explore the safety profile. 200 mg BID 300 mg BID 400 mg BID 500 mg BID Grade 3+ Treatment-Related Adve

  10. Slide 10: Single-agent Activity in AML and HR-MDS

    Emavusertib: Single-agent Activity in AML and HR-MDS All patients 110 * * * * Subset of patients with targeted mutations 100 (SF3B1 / U2AF1 / FLT3 mutation) 90 80 70 With Targeted Mutations Without Targeted Mutations Best Percent Change in Bone M arrow Blast from Baseline (%) 60 50 40 30 20 10 0 -10

  11. Slide 11: Single-agent Activity in R/R AML with Spliceosome Mutation

    Emavusertib: Single-agent Activity in R/R AML with Spliceosome Mutation Duration on # of Prior Blasts Blasts Best Dose (BID) Risk (ELN) Baseline Molecular Mutations emavusertib % Change Therapies Baseline Response1 (mos) -100% 300 mg Intermediate SF3B1, RUNX1, WT1, 1 7 23 0 (CRh) -90% 300 mg Interme

  12. Slide 12: Single-Agent Activity in R/R HR-MDS with Spliceosome Mutation

    Emavusertib: Single-Agent Activity in R/R HR-MDS with Spliceosome Mutation Duration on Blasts # of Prior Blasts Dose (BID) IPSS-R Baseline Molecular Mutations emavusertib Best % Change Therapies Baseline (mos) Response Very High U2AF1 ,ASXL1, NF1, PHF6, GFI1, -82% 200 mg 1 5.7 11 2 Risk KDM6A, TET2

  13. Slide 13: Single-agent Activity in R/R AML with FLT3 Mutation

    Emavusertib: Single-agent Activity in R/R AML with FLT3 Mutation Duration on Blasts Dose # of Prior Blasts Risk (ELN) Baseline Molecular Mutations emavusertib Best % Change (BID) Therapies Baseline (mos) Response1 FLT3 (eradicated at C3D1), ASXL1, BCOR, CEBPA (eradicated at 400 mg Adverse C3D1), CSF

  14. Slide 14: Summary

    Summary • Emavusertib has a manageable safety profile • Demonstrates oral, single-agent, anti-cancer activity in heavily pretreated AML and HR-MDS patients with targeted mutations (U2AF1, SF3B1, or FLT3) • Potential candidate for use in combination therapy for all AML/HR-MDS patients, including pati

  15. Slide 15: Q&A

    Q&A

Curis — EHA 2022 Hybrid Congress on 6ix